RxDoctor Payments DataLook up a doctor →

Eme Igbokwe, MD

Neurology · Bowling Green, KYNPI 1346432507

Payments from drug & device makers

$28,309in general payments, 2019–2025

Across 1,750 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$3K
  • AbbVie$2K
  • UCB, Inc.$2K
  • Amgen$1K
  • Neurocrine Biosciences, Inc.$1K
  • MDD US Operations, LLC$1K
  • plus $17K from 54 others

What the payments were for

  • Food & beverage$27,82298%
  • Education$4882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen186$2,852
AbbVie(2 entities)195$2,226
UCB, Inc.104$2,115
Amgen80$1,434
Neurocrine Biosciences, Inc.53$1,162
MDD US Operations, LLC50$1,105
Novartis80$1,103
Pfizer91$1,089
EMD Serono, Inc.71$996
Lilly USA, LLC62$901
Lundbeck LLC46$779
Neurelis, Inc.41$761
AstraZeneca22$680
Teva Pharmaceuticals USA, Inc.37$664
CSL Behring36$650
Acadia Pharmaceuticals Inc38$628
Jazz Pharmaceuticals Inc.30$563
Supernus Pharmaceuticals, Inc.60$561
Vanda Pharmaceuticals Inc.15$556
Mallinckrodt Hospital Products Inc.23$506
SK Life Science, Inc.27$506
Sunovion Pharmaceuticals Inc.41$483
Catalyst Pharmaceuticals, Inc.22$454
Eisai Inc.21$388
Genentech USA, Inc.21$361
Biohaven Pharmaceuticals, Inc.20$329
Bristol Myers Squibb21$307
Avanir Pharmaceuticals, Inc.23$305
Grifols USA, LLC18$284
Biohaven Pharmaceutical Holding Company Ltd.16$266
Argenx US, Inc.12$243
Johnson & Johnson17$235
Sumitomo Pharma America, Inc.23$220
Octapharma USA, Inc.6$206
Alnylam Pharmaceuticals Inc.12$198
Adamas Pharmaceuticals, Inc.12$197
Livanova USA, Inc.11$181
Amneal Pharmaceuticals LLC11$170
ANI Pharmaceuticals, Inc.9$159
Upsher-smith Laboratories LLC10$152
Otsuka America Pharmaceutical, Inc.9$150
Arbor Pharmaceuticals, Inc.10$149
Sanofi7$147
Mallinckrodt Enterprises LLC7$102
Kyowa Kirin, Inc.4$73
Cycle Pharmaceuticals Inc3$70
Takeda Pharmaceuticals U.S.A., Inc.3$67
TG Therapeutics, Inc.3$53
Zogenix Inc.2$40
Collegium Pharmaceutical, Inc.3$40
Merck1$34
Abbott2$34
Impel Pharmaceuticals Inc.2$32
E.r. Squibb & Sons, L.L.C.2$31
Neuropace, Inc.2$29
Portola Pharmaceuticals, LLC1$23
Idorsia Pharmaceuticals US Inc1$20
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$19
Axsome Therapeutics, Inc.1$19
Boston Scientific1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,309 in reported general payments places this provider in the 80th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$161,189
Medicare patients
582
Services billed
2,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4655$1,079,518
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5017$500,229
IngrezzaValbenazine Tosylate54$439,153
VumerityDiroximel Fumarate47$434,914
HizentraImmun Glob G(Igg)/Pro/Iga 0-5022$237,014
NuplazidPimavanserin Tartrate30$150,579
Kesimpta PenOfatumumab15$145,986
AustedoDeutetrabenazine19$126,880
UbrelvyUbrogepant86$112,981
Nurtec OdtRimegepant Sulfate87$109,249
QuliptaAtogepant69$76,018
GlatopaGlatiramer Acetate23$59,361
EliquisApixaban69$48,401
NuedextaDextromethorphan Hbr/Quinidine22$33,965
Ajovy AutoinjectorFremanezumab-Vfrm38$32,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$284$1,079,51855 claims
CSL BehringPrivigen, Hizentra$650$737,24339 claims
Neurocrine Biosciences, Inc.Ingrezza$1,162$439,15354 claims
BiogenVumerity$2,852$434,91447 claims
AbbVieUbrelvy, Qulipta, Namzaric$2,226$219,493193 claims
PfizerNurtec Odt, Eliquis$1,089$157,649156 claims
Acadia Pharmaceuticals IncNuplazid$628$150,57930 claims
Teva Pharmaceuticals USA, Inc.Austedo$664$126,88019 claims
Avanir Pharmaceuticals, Inc.Nuedexta$305$33,96522 claims
Sunovion Pharmaceuticals Inc.Aptiom$483$30,00812 claims
UCB, Inc.Neupro$2,115$19,00123 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$561$5,67913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 210 neurology providers in Kentucky.

Other neurology in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →